Pasithea Therapeutics Warrants
KTTAW
3 hedge funds and large institutions have $1.12M invested in Pasithea Therapeutics Warrants in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$780K |
| 2 |
KC
Kepos Capital
New York
|
+$312K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$35 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $800K | +$780K | +1,000,000 | New |
|
|
KC
2
Kepos Capital
New York
| $320K | +$312K | +400,000 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| – | +$35 | +45 | New |
|
KTTAW Hedge Fund Activity: Q3 2021 in Review
3 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q3 2021, worth a combined $1.12M.
Buyers outnumbered sellers: 3 funds opened new KTTAW positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $780K.
- 3 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $1.12M of Pasithea Therapeutics Warrants stock for Q3 2021.
- 3 funds opened new Pasithea Therapeutics Warrants positions in Q3 2021 and 0 closed out, a net change of +3 holders.
- The largest Pasithea Therapeutics Warrants buyer in Q3 2021 was Armistice Capital, an estimated $780K added.
Based on aggregated 13F filings for Q3 2021.